The possibility of using subcutaneous and tablet therapy for women with breast cancer means an improvement in the quality of life, as well as improved mental health. It is important that such drugs be included in the drug program as early as possible, says Magdalena Cardinal, President of the OmeaLife Foundation.
Breast cancer treatment is increasingly a long-term treatment lasting many years. We asked Magdalena Cardynal, President of the OneaLife Foundation, to comment on the possibility of using subcutaneous and tablet therapy:
Subcutaneous therapy and tablet therapy are a very good form of treatment, especially for chronically ill patients who will continue this treatment for a long time. In addition to therapeutic benefits, we also see benefits associated with improved quality of life in relation to mental health. Every patient to whom we communicate the information that she has chronic cancer, where the treatment will continue as long as it works, finds it difficult to bear the emotions associated with information about the disease.
When we talk about patients in chronic, palliative care, it is important to offer them therapeutic forms that will not burden their mental health. And certainly monthly hospitalizations do not contribute to this. Especially in the long term, we see a huge impact on the development of anxiety disorders. Subcutaneous and tablet forms are the answer. A key aspect is also that these treatments are less financially burdensome for the state budget - even without the involvement of the entire medical team or hospital pharmacists.
What are we waiting for now? For a drug for HER2-positive patients with advanced or metastatic cancer. It is a two-component drug: trastuzumab and pertuzumab. These are well-known drugs administered separately, as an infusion. Herceptin has been in the subcutaneous form for some time now, so we’ve had a very good experience with it and patients are raving about it. It is important that it does not load the peripheral veins. These innovative forms allow you to achieve exactly the same therapeutic effect, but without increasing the load on the patient’s body.
Tablet formulations are popular with our patients, especially those with early hormone-dependent breast cancer who are at high risk of disease recurrence or metastasis soon after treatment ends. In the case of this group of patients, in 20-30% of patients, the current reimbursable treatment (hormonal therapy) is suboptimal, which is why innovative treatments are so important - I mean abemaciclib in combination with fulvestrant or aromatase. inhibitor. Patients have been waiting for this product for a long time. It is important that this drug be included in the treatment program as soon as possible. It is not only patients who strive for this, but above all doctors and organizations that care about the interests of the patient, and in particular about the high quality of treatment based on the latest therapeutic standards.
Prepared by AK-F
Source: Wprost
I have worked in the news industry for over 8 years. I have a deep understanding of how the news industry works and how to get information out to the public. I am also an author at Daily News Hack, where I mostly cover health news. I have a keen interest in health and fitness, and I firmly believe that knowledge is power when it comes to taking care of your body. I want to help people live healthier lives by sharing my knowledge with them, and LinkedIn is the perfect platform for me to do that.
